Company news

Evolus, Inc. Common Stock news in 2025

Evolus, Inc. Common Stock's news releases, calls and decks from 2025, newest first.

View company

Evolus Reports Third Quarter 2025 Financial Results

November 5, 2025

Evolus to Participate in 2025 Stifel Healthcare Conference

October 28, 2025

Evolus to Report Third Quarter Financial Results on November 5, 2025

October 22, 2025

Evolus Reports Inducement Grants under Nasdaq Listing Rule 5635(4)

October 13, 2025

Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch

September 22, 2025

Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 12, 2025

Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

September 8, 2025

Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp

August 25, 2025

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product

August 20, 2025

Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 5, 2025

Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins

July 31, 2025

Evolus to Report Second Quarter Financial Results on August 5, 2025

July 22, 2025

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France

July 9, 2025

Evolysse™ Recognized in 2025 Shape Skin Awards

June 10, 2025

Evolus Announces Departure of its Chief Financial Officer

May 27, 2025

Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

May 22, 2025

Evolus Reports First Quarter 2025 Results

May 7, 2025

Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

May 5, 2025

Evolus to Report First Quarter Financial Results on May 7, 2025

April 23, 2025

Evolus Announces Commercial Launch of Evolysse™

April 16, 2025

Evolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels

April 15, 2025

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

March 25, 2025

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

March 4, 2025

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

February 27, 2025

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

February 20, 2025

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

February 18, 2025

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

February 12, 2025

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance

January 20, 2025

Calls in 2025

Decks in 2025